A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib

PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

June 28, 2021

Primary Completion Date

June 1, 2022

Study Completion Date

June 1, 2022

Conditions
Advanced Solid Tumours
Interventions
DRUG

Adavosertib

Patients will receive a single dose of Adavosertib orally in arm A, B, and C.

DRUG

Itraconazole

Patients will receive Itraconazole orally once daily for 7 days in arm A.

DRUG

Rifampicin

Patients will receive Rifampicin orally once daily for 13 days in arm B.

DRUG

Omeprazole

Patients will receive Omeprazole orally once daily for 5 days in arm C.

Trial Locations (5)

28041

Research Site, Madrid

29010

Research Site, Málaga

75230

Research Site, Dallas

78758

Research Site, Austin

97213

Research Site, Portland

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY